Consensus Incyte Corporation Deutsche Boerse AG

Stocks

ICY

US45337C1027

Pharmaceuticals

Market Closed - Deutsche Boerse AG 02:01:10 2026-10-02 EDT			5-day change	1st Jan Change
103.60 ^EUR	-2.54%		-5.47%	+23.45%

10-02	S&P 500 Posts Slight Weekly Drop as Health Care, Financials Weigh	MT
10-01	Wells Fargo Adjusts Price Target on Incyte to $128 From $116, Keeps Equalweight Rating	MT

f100869d97ee4099105209b4b802.O59CMRE2Cm17yPUb0zZ8VWQk2nfIivSg4co6dSOvDTk.Ft03fzxZTx0h-plvkHIRYBdzmT6w87rZsPsLHhrrbF5x5g1Tf096IDiAhg~6862b3e0093281aee3de958c27bd4045

Analysts' recommendations: Incyte Corporation

10-01	Wells Fargo Adjusts Price Target on Incyte to $128 From $116, Keeps Equalweight Rating	MT
09-28	HC Wainwright Adjusts Price Target on Incyte to $152 From $150, Maintains Buy Rating	MT
09-28	JPMorgan Adjusts Price Target on Incyte to $123 From $120, Keeps Neutral Rating	MT
08-20	Canaccord Genuity Initiates Incyte at Buy With $152 Price Target	MT
08-17	Piper Sandler Adjusts Price Target on Incyte to $130 From $110, Maintains Overweight Rating	MT
08-13	Bernstein Adjusts Price Target on Incyte to $104 From $99, Keeps Market Perform Rating	MT
08-03	Mizuho Adjusts Price Target on Incyte to $137 From $121	MT
08-03	Leerink Partners Adjusts Price Target on Incyte to $155 From $131, Maintains Outperform Rating	MT
07-31	Argus Adjusts Price Target on Incyte to $140 From $115, Maintains Buy Rating	MT
07-30	JPMorgan Adjusts Price Target on Incyte to $120 From $110, Maintains Neutral Rating	MT
07-29	Incyte's Solid Q2 Seen Funding Strategy Beyond Jakafi Patent Expiration, RBC Says	MT
07-29	TD Cowen Adjusts Incyte Price Target to $138 From $124, Maintains Buy Rating	MT
07-29	Barclays Adjusts Incyte Price Target to $139 From $134, Maintains Overweight Rating	MT
07-29	Morgan Stanley Adjusts Incyte PT to $119 From $104, Maintains Equal Weight Rating	MT
07-29	BMO Capital Adjusts Incyte Price Target to $130 From $112, Maintains Market Perform Rating	MT
07-29	Jefferies & Co Adjusts Incyte Price Target to $115 From $105, Maintains Hold Rating	MT
07-29	Guggenheim Adjusts Incyte Price Target to $150 From $136, Maintains Buy Rating	MT
07-29	HC Wainwright Raises Incyte Price Target to $150 From $140, Maintains Buy Rating	MT
07-29	Goldman Sachs Adjusts Incyte Price Target to $118 From $110, Maintains Neutral Rating	MT
07-29	RBC Raises Price Target on Incyte to $109 From $99, Keeps Sector Perform Rating	MT
07-28	Oppenheimer Raises Incyte Price Target to $120 From $107	MT
07-28	Stifel Raises Incyte Price Target to $145 From $123, Buy Rating Kept	MT
07-28	Wells Fargo Adjusts Price Target on Incyte to $116 From $101	MT
07-23	JPMorgan Adjusts Price Target on Incyte to $110 From $105, Maintains Neutral Rating	MT
07-22	Morgan Stanley Adjusts Price Target on Incyte to $104 From $103, Maintains Equalweight Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+16.27%
	JOHNSON & JOHNSON					+9.08%
	ABBVIE INC.					+6.1%
	MERCK & CO., INC.					+7.94%
	ROCHE HOLDING AG					+8.57%
	NOVARTIS AG					+8.12%
	ASTRAZENECA PLC					+34.02%
	AMGEN INC.					-3%
	GILEAD SCIENCES, INC.					+9.61%
	Average					+10.75%
	Weighted average by Cap.					+11.42%